

Special Issue

Engineering of Functional Micro-/Nanoparticles for Stem Cell Therapy

Message from the Guest Editor

A large number of clinical trials have demonstrated the effectiveness of stem cell therapy as an alternative therapeutic paradigm. For an ideal therapeutic effect, a sufficient number of stem cells must be retained at the injury site or migrate to the targeted tissues to exert long-term biological effects. In addition, the successful implementation of stem cell therapy requires a comprehensive understanding of cell fate after transplantation, including cell localization, survival, and differentiation. Despite the obvious merits of stem cell therapy, so far, it is difficult to realize the aforementioned functional therapeutic benefits by using stem cells alone.

Recent research has demonstrated the distinct effects of functional micro-/nanoparticles, thereby paving the way for stem cell engineering as an effective disease treatment. This Special Issue aims to include research on the design, fabrication, and multiple biomedical applications of functional micro-/nanoparticles for enhancing stem cell therapy. All relevant basic and clinical results will be considered for publication in this Special Issue.

Guest Editor

Dr. Ming Ma

State Key Laboratory of High Performance Ceramics and Superfine Microstructures, Shanghai Institute of Ceramics, Chinese Academy of Sciences, Shanghai 200050, China

Deadline for manuscript submissions

closed (30 September 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/150140

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).